3T MRI-Compatible Small Body Array Gets FDA Nod
Featuring a lightweight body contouring design, the Small Body Array reportedly facilitates optimal signal-to-noise ratio (SNR) and between 10 and 40 percent faster throughput.
The Food and Drug Administration (FDA) has granted 510(k) clearance for a 3T magnetic resonance imaging (MRI)-compatible Small Body Array, which emphasizes a body contouring design and coils that are 80 percent lighter than conventional coils.
The body-hugging design of the Small Body Array adapts to a wide range of patient anatomies and sizes, according to InkSpace Imaging, the developer of the Small Body Array. The company emphasized that the Small Body Array provides optimal signal-to-noise ration (SNR), which improves detection of subtle abnormalities that may be missed by conventional coils.
In addition to increased patient comfort, InkSpace Imaging said the Small Body Array offers high coil element density, which helps streamline MRI acquisition. The company noted that the coils with the Small Body Array allow up to 40 percent faster throughput.
“The FDA clearance of InkSpace Imaging's Small Body Array marks a pivotal moment in MRI technology advancement. Our suite of MR coils is a game-changer, offering total freedom in coil positioning and handling,” noted Peter Fischer, the CEO of InkSpace Imaging. “What's truly impressive is how our thin flexible coil contours to each patient's body, offering comfort while enhancing image quality. It's a win-win for patients and health-care providers alike."
InkSpace Imaging said the Small Body Array is compatible with the Magnetom Skyra (Siemens Healthineers) and Magnetom Vida (Siemens Healthineers) series 3T MRI scanners.
Recent Videos
Related Content
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025Article
New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Article
Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025Article
In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
